Zoetis (NYSE:ZTS) Hits New 12-Month Low – Here’s Why

Zoetis Inc. (NYSE:ZTS) reached a new 52-week low on Friday . The stock traded as low as $114.44 and last traded at $114.6030, with a volume of 2084610 shares trading hands. The stock had previously closed at $115.99.

Analyst Ratings Changes

Several brokerages recently weighed in on ZTS. Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, March 12th. Barclays began coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research report on Thursday, December 18th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, Zoetis has an average rating of “Hold” and an average target price of $152.91.

Zoetis Price Performance

The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $48.73 billion, a PE ratio of 19.17, a PEG ratio of 1.77 and a beta of 0.95. The firm’s fifty day simple moving average is $124.35 and its 200-day simple moving average is $130.44.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Institutional Investors Weigh In On Zoetis

Hedge funds have recently added to or reduced their stakes in the stock. Halbert Hargrove Global Advisors LLC boosted its position in Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. Global Wealth Strategies & Associates bought a new position in shares of Zoetis in the fourth quarter worth about $25,000. Prosperity Bancshares Inc bought a new stake in Zoetis during the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis during the 4th quarter valued at $30,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis in the 3rd quarter worth $31,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.